Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Gains from Sales and Divestitures (2023 - 2025)

Dna X (SONM) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $42956.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures fell 10.38% year-over-year to $42956.0, compared with a TTM value of $42956.0 through Sep 2025, down 10.38%, and an annual FY2024 reading of $57621.0, down 90.69% over the prior year.
  • Gains from Sales and Divestitures was $42956.0 for Q3 2025 at Dna X, down from $773960.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $773960.0 in Q2 2025 and bottomed at $2149.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 3 years is $245271.4, with a median of $47929.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 92.08% in 2024, then surged 1907.94% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $619042.0 in 2023, then tumbled by 90.69% to $57621.0 in 2024, then decreased by 25.45% to $42956.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for SONM at $42956.0 in Q3 2025, $773960.0 in Q2 2025, and $2149.0 in Q1 2025.